Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference, taking place June 15-16, 2026. The fireside chat will be available on demand beginning June 15 at 7:00 a.m. EDT. This engagement provides an opportunity for investors and industry observers to gain insights into Helus Pharma's clinical development programs and strategic direction.
Helus Pharma, the commercial operating name of Cybin Inc., is focused on developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma intends to improve the treatment landscape through NSAs that provide durable improvements in mental health.
The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 development for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.
The H.C. Wainwright conference serves as a platform for emerging biotechnology companies to present their latest developments to a targeted audience of investors, analysts, and industry professionals. Amir Inamdar's participation underscores Helus Pharma's commitment to advancing its pipeline and communicating its progress to the investment community. The conference is expected to draw attention to the company's innovative approach to mental health treatment and its potential to address significant unmet medical needs.
For more information about Helus Pharma and its pipeline, visit the company's website at www.helus.com or follow the team on social media platforms. The full press release is available at https://ibn.fm/KsnJW.
